Wasatch Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wasatch Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-157,681	Closed	-$2.03M	–	391
2014 Q4	$2.03M	Sell	157,681 -81,348	-34%	-$1.02M	0.02%	313
2014 Q3	$2.94M	Sell	239,029 -171,672	-42%	-$1.99M	0.03%	291
2014 Q2	$6.5M	Buy	410,701 +4,144	+1%	+$59.1K	0.06%	236
2014 Q1	$6.15M	Sell	406,557 -444,008	-52%	-$5.01M	0.06%	236
2013 Q4	$6.48M	Sell	850,565 -189,126	-18%	-$1.02M	0.06%	225
2013 Q3	$3.51M	Buy	1,039,691 +298,080	+40%	+$786K	0.04%	268
2013 Q2	$1.82M	Buy	+741,611	New	+$1.78M	0.02%	314

Other funds holding HZNP

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Wasatch Advisors's HZNP Position: Q1 2015 in Review

Wasatch Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2015, closing a stake of 157,681 shares — an estimated $2.03M sold.

Wasatch Advisors first reported a position in HZNP in Q2 2013 and held it in 7 quarters. The position peaked at $6.5M in Q2 2014. 177 funds tracked by Wall St. Rank hold HZNP as of Q1 2015.

Wasatch Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2015 after selling out during the quarter.
Wasatch Advisors sold 157,681 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2015, an estimated $2.03M.
Wasatch Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 7 quarters.
Wasatch Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.5M in Q2 2014.
177 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2015.

Based on Wasatch Advisors's 13F filing for Q1 2015, filed 14 May 2015.